REGENXBIO is a Maryland-based biotechnology company that researches and develops gene therapeutics for the treatment of retinal, metabolic, and neurodegenerative diseases... Read more
REGENXBIO is a Maryland-based biotechnology company that researches and develops gene therapeutics for the treatment of retinal, metabolic, and neurodegenerative diseases... Read more
News
May 15, 2026
Seeking Alpha
Regenxbio: Regenxbio outlines potential accelerated approval path for RGX-202 in 2027 following pivotal Phase III primary endpoint result
May 15, 2026
Clinical Trials Arena
Regenxbio: REGENXBIO to push for accelerated approval of DMD gene therapy
May 14, 2026
Yahoo
Regenxbio: Regenxbio Shares Rise After Positive Duchenne Trial Results
May 07, 2026
centralcharts
Press Release: Regenxbio : REGENXBIO Announces Presentations at the American Society of Gene & Cell Therapy 2026 Annual Meeting
Apr 14, 2026
FinanzNachrichten
Regenxbio: Bronstein, Gewirtz & Grossman, LLC: Bronstein, Gewirtz & Grossman LLC Urges REGENXBIO Inc. Investors to Act: Class Action Filed Alleging Investor Harm
Apr 14, 2026
Benzinga
Regenxbio: RGNX Deadline Today: RGRX Investors Have Opportunity to Lead REGENXBIO, Inc. Securities Fraud Lawsuit
Apr 11, 2026
PR-Inside
Press Release: Regenxbio : Pomerantz LLP Notifies Shareholders of Class Action Against REGENXBIO ...
Apr 07, 2026
PR-Inside
Press Release: Regenxbio : Lifshitz Law PLLC Announces Investigations of REGENXBIO Inc. (NASDAQ: ...
Mar 31, 2026
BioCentury
Regenxbio: FDA exploring path forward for therapies that received CRLs
Mar 30, 2026
Benzinga
Regenxbio: RGNX Investors Have Opportunity to Lead REGENXBIO Inc. Securities Fraud Lawsuit with the Schall Law Firm
Regenxbio Competitors
1
2
3
4
5
6
7
8
9
10